Grup de recerca de biomarcadors en càncer (GReBiC)
- Nombre de publicacions
- 495
Publicacions
-
Lange, B; Khan, P; Kalmambetova, G; Al-Darraji, HA; Alland, D; Antonenka, U; Brown, T; Balcells, ME; Blakemore, R; Denkinger, CM; Dheda, K; Hoffmann, H; Kadyrov, A; Lemaitre, N; Miller, MB; Nikolayevskyy, V; Ntinginya, EN; Ozkutuk, N; Palacios, JJ; Popowitch, EB; Porcel, JM; Teo, J; Theron, G; Kranzer, K
Diagnostic accuracy of the Xpert (R) MTB/RIF cycle threshold level to predict smear positivity: a meta-analysis
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE 21 493-502. .
-
Porcel, JM
Diagnostic usefulness of pleural fluid total leukocyte count and differential
REVISTA CLINICA ESPANOLA 217 149-150. .
-
Porcel, JM; Lui, MMS; Lerner, AD; Davies, HE; Feller-Kopman, D; Lee, YCG
Comparing approaches to the management of malignant pleural effusions
EXPERT REVIEW OF RESPIRATORY MEDICINE 11 273-284. .
-
Irigoyen A; Gallego J; Guillén Ponce C; Vera R; Iranzo V; Ales I; Arévalo S; Pisa A; Martín M; Salud A; Falcó E; Sáenz A; Manzano Mozo JL; Pulido G; Martínez Galán J; Pazo-Cid R; Rivera F; García García T; Serra O; Fernández Parra EM; Hurtado A; Gómez Reina MJ; López Gomez LJ; Martínez Ortega E; Benavides M; Aranda E
Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety results of a phase IIb randomised study from the Spanish TTD Collaborative Group
EUROPEAN JOURNAL OF CANCER 75 73-82. .
-
Llombart-Cussac, A; Cortes, J; Pare, L; Galvan, P; Bermejo, B; Martinez, N; Vidal, M; Pernas, S; Lopez, R; Muñoz M; Nuciforo, P; Morales, S; Oliveira, M; de la Peña L; Pelaez, A; Prat, A
HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial
LANCET ONCOLOGY 18 545-554. .
-
Porcel, JM; Quiros, M; Gatius, S; Bielsa, S
Examination of cytological smears and cell blocks of pleural fluid: Complementary diagnostic value for malignant effusions
REVISTA CLINICA ESPANOLA 217 144-148. .
-
Fernandez-Martinez, A; Pascual, T; Perrone, G; Morales, S; de la Haba, J; Gonzalez-Rivera, M; Galvan, P; Zalfa, F; Amato, M; Gonzalez, L; Prats, M; Rojo, F; Manso, L; Pare, L; Alonso, I; Albanell, J; Vivancos, A; Gonzalez, A; Matito, J; Gonzalez, S; Fernandez, P; Adamo, B; Muñoz M; Viladot, M; Font, C; Aya, F; Vidal, M; Caballero, R; Carrasco, E; Altomare, V; Tonini, G; Prat, A; Martin, M
Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer
Oncotarget 8 21930-21937. .
-
Gasol Cudos, A.; Morales Murillo, S.; Panades Siurana, M. J.; Vilardell Villellas, F.; Canosa Morales, C.; Mele Olive, J.; Iglesias Martinez, E.; Salud Salvia, A.
Change in treatment decisions according to Oncotype Dx Recurrence Score in node positive and negative, estrogen-receptor positive (ER+), HER2 negative breast cancer in a single institution
BREAST 32 92-93. .
-
Prat, A.; Ortega, V.; Villagrasa, P.; Pare, L.; Galvan, P.; Oliveira, M.; Nuciforo, P.; Lluch, A.; Morales, S.; Amillano, K.; Lopez, R.; Gonzalez, R.; Manso, L.; Martinez, J.; Llombart, A.; De la Pena, L.; Di Cosimo, S.; Rubio, I. T.; Harbeck, N.; Baselga, J.; Cortes, J.
Efficacy and gene expression results from SOLTI1007 NEOERIBULIN phase II clinical trial in HER2-negative early breast cancer
CANCER RESEARCH 77 -. .
-
Porcel, JM; Valencia, H; Bielsa, S
Manual Intrapleural Saline Flushing Plus Urokinase: A Potentially Useful Therapy for Complicated Parapneumonic Effusions and Empyemas
Lung 195 135-138. .
-
Patel, UB; Brown, G; Machado, I; Santos-Cores, J; Pericay, C; Ballesteros, E; Salud, A; Isabel-Gil, M; Montagut, C; Maurel, J; Ramon-Ayuso, J; Martin, N; Estevan, R; Fernandez-Martos, C
MRI assessment and outcomes in patients receiving neoadjuvant chemotherapy only for primary rectal cancer: long-term results from the GEMCAD 0801 trial
ANNALS OF ONCOLOGY 28 344-353. .
-
Aparicio, AP; Castan, JC; Pare, L; Galvan, P; Bermejo, B; Martinez, N; Vidal, M; Pernas, S; Lopez, R; Munoz, M; Nuciforo, P; Fasani, R; Morales, S; Oliveira, M; de la Pena, L; Pelaez, A; Llombart, A
PAM50 intrinsic subtype as a predictor of pathological complete response following neoadjuvant dual HER2 blockade without chemotherapy in HER2-positive breast cancer: First results of the PAMELA clinical trial
CANCER RESEARCH 77 -. .
